ALC - Alcon Inc.
58.92 +0.52 (0.89%)
Before hours: 9:05AM EDT
| Previous Close | 57.32 |
| Open | 58.14 |
| Bid | 58.76 x 900 |
| Ask | 59.00 x 800 |
| Day's Range | 57.82 - 58.79 |
| 52 Week Range | 39.37 - 65.37 |
| Volume | 1,550,708 |
| Avg. Volume | 1,458,960 |
| Market Cap | 28.42B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.45 |
- Business Wire
Alcon Prices US$750.0 Million Senior Notes Offering
Alcon prices US$750.0 million senior notes offering
- Motley Fool
Alcon Inc (ALC) Q1 2020 Earnings Call Transcript
Joining me on today's call are David Endicott, our Chief Executive Officer; and Tim Stonesifer, our Chief Financial Officer. Accordingly, you should not place undue reliance on any forward-looking statements.
- Business Wire
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual American Society of Cataract and Refractive Surgery 2020 Annual Meeting
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual ASCRS 2020
- Business Wire
Alcon Shareholders Approve All Proposed Resolutions at the 2020 Annual General Meeting
Alcon shareholders approve all proposed resolutions at the 2020 Annual General Meeting
- Business Wire
Alcon Announces European Launch of Vivity, the Only Presbyopia-correcting Intraocular Lens With X-WAVE Technology
Alcon announces European launch of Vivity, the only presbyopia-correcting intraocular lens with X-WAVE technology
- Business Wire
Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
- Reuters
Swiss eyecare company Alcon posts another loss, announces revamp
Swiss-listed eyecare company Alcon <ALCC.S> reported another quarterly loss, specified its profit outlook, boosted projections for the cost of its spinoff from Novartis <NOVN.S> and announced a $300 million restructuring program. The company now expects a core operating margin of 17-17.5% for 2019, compared with 17-18% previously and tweaked its sales goal to 4-5% growth, from 3-5%. Alcon increased its expected separation costs from Novartis to $500 million, from $300 million, due to work on IT systems, among other things.
- Motley Fool
Alcon, Inc. (ALC) Q2 2019 Earnings Call Transcript
ALC earnings call for the period ending June 30, 2019.
- Zacks
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
